Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alexion pharmaceuticals
3
×
biotech
boston
3
×
boston blog main
boston top stories
clinical trials
deals
life sciences
national blog main
boehringer ingelheim
fda
hepatitis b
national top stories
rna interference
alnylam pharmaceutials
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
arrowhead pharmaceuticals
autoimmune disorders
complement system
dicerna pharamceuticals
dicerna pharmaceuticals
eli lilly
generalized myasthenia gravis
hepatitis b virus
hereditary transthyretin amyloidosis
immune-mediated necrotizing myopathy
indiana blog main
indiana top stories
johnson & johnson
neurodegenerative diseases
patisiran
primary hyperoxaluria
ra pharmaceuticals
rare disease drugs
roche
san francisco blog main
san francisco top stories
ucb
wisconsin blog main
What
medicines
pharma
3
×
deal
dicerna
disease
drug
pharmaceuticals
abandoning
ago
alternative
autoimmune
baggage
candidate
caught
causing
companies
cuts
development
expensive
eye
free
gene
gets
hepatitis
intended
interference
lead
long
pay
potential
producing
protein
ra
research
rna
rnai
roche
signs
small
stakes
Language
unset
Current search:
pharma
×
boston
×
" alexion pharmaceuticals "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M